KineMed Inc. ( www.kinemed.com ) and CHDI Foundation, Inc. announced today a collaboration to investigate the role of the metabolism of cholesterol and other lipids in Huntington’s disease (HD). Research leading up to this study suggests that the homeostatic processes that control the balance of cholesterol in the brain are altered in HD patients.
The collaboration will utilize KineMed’s extensive experience in cholesterol metabolic studies and will quantify physiologic and pathologic brain lipid synthesis in HD. KineMed aims to develop lipid kinetic biomarkers, including the dynamics of cholesterol, phospholipids and galactosylceramide in the brain, as well as the synthesis of plasma 24-hydroxy cholesterol. If successful, these kinetic biomarkers will be used as indicators of disease progression and to evaluate the effectiveness of therapeutic interventions.
“Developing a biomarker that measures cholesterol metabolism in the living brain from a blood sample is a key to developing better medicines,” said Dr. Scott Turner, EVP, R&D at KineMed, “Altered cholesterol metabolism is also implicated as a pathogenic mechanism in other CNS diseases such as Alzheimer’s, Parkinson’s and ALS, as well as Huntington’s.”
“Changes in sterols are one of a number of alterations that research has identified in HD patients. Our collaboration with KineMed will help us further explore this and could lead us to additional targets for therapeutic intervention as well as handles on disease progression in the future,” said Dr. Deanna Marchionini, Director, Discovery Biology at CHDI.
Source: BUSINESS WIRE